Annexon (ANNX) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing two late-stage programs, tanruprubart for Guillain-Barré Syndrome (GBS) and vonaprument for geographic atrophy (GA) in dry age-related macular degeneration, both targeting large, underserved markets.

• Pipeline includes next-generation oral C1 inhibitor ANX1502 and additional indications in neurodegenerative and autoimmune diseases.

• C1q inhibition platform offers a differentiated approach by stopping neuroinflammation at its source, potentially providing advantages over C3 and C5 inhibitors.

Market opportunity and competitive positioning

• C1q inhibition is positioned as the next generation after C3 and C5 inhibition, with significant acquisition activity in the sector highlighting market value.

• Vonaprument and tanruprubart are described as potential blockbusters, with vonaprument aiming to be the first vision-preserving therapy for GA and tanruprubart as the first targeted rapid-acting GBS treatment.

• GA and GBS represent multi-billion dollar opportunities due to high unmet need and large patient populations.

Clinical development and milestones

• Tanruprubart: EU MAA filed January 2026, US BLA planned for 2026, with initial FORWARD study data anticipated in 2026.

• Vonaprument: Topline Phase 3 data expected Q4 2026, with global pivotal program underway and regulatory designations including PRIME and Fast Track.

• ANX1502: Proof-of-concept study in cold agglutinin disease (CAD) ongoing, with completion anticipated in 2026.